United States Patent 8,524,773: Claim Scope, Tecfidera Exclusivity, Litigation, and Patent Landscape

U.S. Patent No. 8,524,773 protects selected methods of treating multiple sclerosis using methyl hydrogen fumarate generated from orally administered dimethyl fumarate. Its narrowest commercial relevance is tied to oral dimethyl fumarate solid dosage forms, including tablets, capsules, and micro-tablets. The patent does not claim dimethyl fumarate as a chemical compound, a particular drug product brand, or every use of fumarate esters. Its value depends on whether an accused product practices the claimed treatment method and whether the patent remains enforceable against the relevant generic manufacturer.

The claims are method-of-treatment claims with a cascading structure:

Claim	Core subject matter	Commercial significance
1	Contacting a multiple-sclerosis patient's peripheral blood mononuclear cells or monocytes with methyl hydrogen fumarate	Broadest independent claim, but technically specific
2	Administering an oral preparation consisting essentially of dimethyl fumarate, which is converted in vivo to methyl hydrogen fumarate	Main claim directed to oral dimethyl fumarate therapy
3	Solid dosage forms including micro-pellets, micro-tablets, granulates, capsules, and tablets	Covers multiple oral dosage configurations
4	Tablet or capsule dosage forms	Important for conventional generic products
5	Micro-tablet dosage forms	Narrowest and most formulation-specific claim

What does U.S. Patent 8,524,773 cover?

The patent covers a treatment pathway in which methyl hydrogen fumarate, also known as monomethyl fumarate, contacts immune cells associated with multiple sclerosis. Claim 1 is written around the biological event rather than the act of administering a finished drug product.

Claim 2 supplies the principal bridge to commercial dimethyl fumarate products. It requires:

A patient in need of treatment for multiple sclerosis.
An oral pharmaceutical preparation.
A preparation consisting essentially of dimethyl fumarate.
Conversion of dimethyl fumarate in the patient's body into methyl hydrogen fumarate.

Claims 3 through 5 narrow claim 2 by specifying the dosage form. A product administered as a tablet or capsule would fall within the literal wording of claim 4 if the other limitations are met. A micro-tablet product would implicate claim 5.

The patent therefore targets the therapeutic use of dimethyl fumarate rather than the compound itself. A company that manufactures dimethyl fumarate for a nonmedical purpose, or for a use outside multiple sclerosis, does not necessarily practice these claims. A generic company selling oral dimethyl fumarate for multiple sclerosis presents a materially greater infringement risk.

How should the claim language be interpreted?

Claim 1: contact with peripheral blood mononuclear cells or monocytes

Claim 1 requires contacting either:

Peripheral blood mononuclear cells, commonly called PBMCs; or
Monocytes,

with methyl hydrogen fumarate.

The claim does not expressly require that the treating party administer methyl hydrogen fumarate as a finished product. It covers a method in which the relevant patient cells are exposed to the active metabolite. The claim also does not specify a dose, dosing frequency, concentration, treatment duration, disease stage, or particular mechanism of action.

Its breadth is limited by the cell-contacting requirement. In an infringement dispute, the patentee would need to connect the accused treatment method to contact between methyl hydrogen fumarate and the specified patient cells. That requirement may create proof issues because an ordinary prescription label usually describes administration of dimethyl fumarate, not direct measurement of intracellular or blood-cell exposure to methyl hydrogen fumarate.

Claim 2: dimethyl fumarate as the administered product

Claim 2 is commercially more direct. It recites oral administration of a pharmaceutical preparation consisting essentially of dimethyl fumarate. The claim treats dimethyl fumarate as a prodrug or precursor that is converted in vivo to methyl hydrogen fumarate.

The phrase "consisting essentially of" is materially different from "consisting of." It generally permits components that do not materially alter the basic and novel characteristics of the claimed preparation. Excipients, capsule materials, coatings, stabilizers, and manufacturing aids may be compatible with the claim if they do not change the preparation's essential characteristics.

The claim does not require a particular brand, trade name, manufacturer, salt, release profile, strength, or excipient system. A generic product could therefore meet the claim even if its inactive ingredients and manufacturing process differ from the reference product.

Claims 3 and 4: oral solid dosage forms

Claim 3 lists micro-pellets, micro-tablets, granulates, capsules, and tablets. Claim 4 narrows the scope to tablets or capsules.

A conventional delayed-release, enteric-coated, immediate-release, or other solid oral presentation may fall within claim 4 if it otherwise satisfies claim 2. The claim language does not appear to require a particular release mechanism. A formulation designed to reduce gastrointestinal irritation could still be within the claim if it is an oral tablet or capsule containing a preparation consisting essentially of dimethyl fumarate.

Claim 5: micro-tablets

Claim 5 is limited to micro-tablets. This narrower claim could be relevant to multiparticulate dosage forms in which small compressed units are placed into a capsule or incorporated into another oral presentation.

The claim provides a potential fallback position if claims directed to tablets or capsules are narrowed or invalidated. Its practical value depends on the physical construction of the accused product and on whether the product's labeling or technical documentation establishes that it contains micro-tablets rather than granules, pellets, or conventional tablets.

What patents protect dimethyl fumarate treatment for multiple sclerosis?

The commercial patent estate surrounding dimethyl fumarate for multiple sclerosis has included several Biogen-related patents and patent families. The most important distinction is between patents directed to:

The therapeutic use of fumarate compounds.
Oral dimethyl fumarate administration.
Dosage forms and release characteristics.
Methods involving methyl hydrogen fumarate or monomethyl fumarate.
Manufacturing and pharmaceutical composition technology.

U.S. Patent 8,524,773 belongs to the method-of-use portion of that estate. It should not be treated as a composition-of-matter patent covering dimethyl fumarate itself.

Patent category	Typical protected subject matter	Relevance to generic entry
Compound patents	Chemical identity of dimethyl fumarate or related fumarates	Potentially broad, but often expired earlier or unavailable for a known compound
Method patents	Treating multiple sclerosis with dimethyl fumarate or methyl hydrogen fumarate	Can support Orange Book listing and Paragraph IV litigation
Formulation patents	Tablets, capsules, delayed release, multiparticulates, coatings, and excipients	May delay or complicate a generic launch
Manufacturing patents	Synthesis, purification, crystallization, particle size, and process controls	Creates supply-chain and process risks
Regulatory exclusivity	New chemical entity and clinical-approval exclusivity	Operates independently from patent term

The broader Tecfidera estate has included U.S. Patent Nos. 7,619,001, 8,399,514, 8,524,773, and 8,759,393, among other patents and continuations or related rights. Patent relevance depends on the specific Orange Book listing, asserted claims, terminal disclaimers, patent-term adjustment, and litigation history. The U.S. Food and Drug Administration's Orange Book remains the controlling commercial reference for patents listed against an approved small-molecule product. [1]

When does U.S. Patent 8,524,773 lose exclusivity?

The patent's term is generally measured from the applicable U.S. filing framework and may include patent-term adjustment. Public patent records identify a 2028 expiration period for the patent, subject to the official USPTO term calculation and any applicable terminal-disclaimer or post-grant events. [2]

Patent expiration is separate from FDA regulatory exclusivity. Tecfidera received FDA approval on March 27, 2013. As a new chemical entity, dimethyl fumarate received five years of statutory exclusivity, which generally prevented submission of an abbreviated new drug application relying on the approval during the exclusivity period. That regulatory exclusivity expired in 2018, while relevant patent rights continued beyond that date. [3]

Exclusivity mechanism	Approximate event	Effect
FDA approval	March 27, 2013	Tecfidera approved for relapsing forms of multiple sclerosis
NCE exclusivity	Through approximately March 27, 2018	Restricted certain ANDA submissions
Patent term for U.S. 8,524,773	Public records identify a 2028 expiration period	Potentially restricts infringing commercial use after approval
Patent term adjustment	Incorporated into official USPTO calculation	Can alter the effective expiration date
Litigation outcomes	Case-specific	May invalidate, narrow, or leave claims enforceable

An ANDA applicant can receive FDA approval after regulatory exclusivity expires but still face a launch bar based on listed patents. Patent expiry, invalidity, a noninfringement judgment, a covenant not to sue, or a settlement can remove that barrier.

What is the Orange Book status of the patent?

The commercial question is whether U.S. Patent 8,524,773 is listed for the relevant Tecfidera reference product and what use code or product presentation it covers. Orange Book listing practice has changed over time, and listed patents can be delisted, corrected, or challenged under the Hatch-Waxman framework.

A listed method patent generally requires an ANDA applicant to certify under Paragraph I, II, III, or IV. A Paragraph IV certification states that the patent is invalid, unenforceable, or will not be infringed by the proposed product. The certification can trigger patent litigation if the NDA holder sues within the statutory period.

The existence of an Orange Book listing does not establish validity. It establishes a regulatory notice and litigation pathway. Courts, not the FDA, decide infringement, validity, and enforceability.

Which companies challenged Tecfidera patents?

Generic dimethyl fumarate litigation involved multiple ANDA applicants and Biogen-related patent claims. The most prominent Federal Circuit decision involved Biogen's U.S. Patent No. 8,399,514 and Mylan's proposed generic dimethyl fumarate product. The Federal Circuit affirmed the district court's determination that the asserted patent was invalid for obviousness. [4]

That decision matters to the overall Tecfidera landscape, but it should not automatically be treated as a judgment concerning every patent in the estate. U.S. Patent 8,524,773 must be analyzed independently. A decision invalidating or narrowing one patent does not automatically invalidate a separate patent with different claims, specifications, prosecution history, or priority chain.

The relevant litigation questions for the '773 patent include:

Whether an ANDA applicant certified Paragraph IV against the patent.
Whether the patent holder filed suit within the statutory period.
Whether the asserted claims survived claim construction.
Whether the accused product's dosage form was a tablet, capsule, micro-tablet, or another form.
Whether the applicant carved out the multiple-sclerosis indication.
Whether a settlement imposed a licensed or agreed launch date.
Whether the patent was later disclaimed, reissued, or removed from the Orange Book.

How strong is the patent estate for dimethyl fumarate?

The estate has mixed strength because its patents occupy different technical and legal positions.

Strengths

U.S. Patent 8,524,773 has several features that can support enforcement:

It is directed to the approved therapeutic use of dimethyl fumarate.
Claim 2 reaches oral administration rather than a particular manufacturing process.
Claims 3 and 4 cover conventional solid dosage forms used by many generic products.
The claims do not require the same inactive ingredients as the reference product.
A generic label for multiple sclerosis can create a direct connection between the product and the claimed method.

Vulnerabilities

The patent also has litigation exposure:

Claim 1 requires proof of contact with specific immune-cell populations.
The conversion of dimethyl fumarate into methyl hydrogen fumarate may raise claim-construction and proof questions.
The prior art includes fumaric acid ester treatments and multiple-sclerosis applications, creating obviousness issues.
The patent may face written-description or enablement arguments depending on the full specification and prosecution record.
A generic applicant may pursue a section viii carve-out for a patented method while retaining approval for noninfringing indications, if permitted by the approved labeling.
Claims 3 through 5 may be vulnerable if the product's dosage form is characterized differently from the claim language.

The patent's commercial strength is therefore greater against a conventional generic label that expressly identifies multiple sclerosis treatment with oral dimethyl fumarate than against a product designed around a narrow indication or a materially different dosage form.

What generic launch risks exist for dimethyl fumarate?

A generic launch strategy can follow several paths.

Launch strategy	Principal legal theory	Business risk
Paragraph III certification	Wait for listed patent expiry	Delayed entry, lower litigation cost
Paragraph IV certification	Assert invalidity or noninfringement	Litigation, possible 30-month stay
Section viii carve-out	Remove patented indication from labeling	Reduced market access and labeling constraints
At-risk launch	Launch before final resolution	Damages, injunction, treble-damages exposure
Settlement or license	Enter on an agreed date or terms	Delay, royalty or supply obligations

The main risk under claim 4 is a generic oral tablet or capsule labeled for multiple sclerosis. The applicant may argue that the method is not infringed because the claim requires methyl hydrogen fumarate contact with PBMCs or monocytes, or because the product does not satisfy "consisting essentially of." Those arguments must be assessed against the specification, prosecution history, product composition, and label.

A product using dimethyl fumarate for a different approved indication could reduce method-of-use exposure, but the analysis would depend on the actual label and physician behavior. Induced infringement can arise from promotional materials, prescribing instructions, or other evidence showing encouragement of the patented use.

What formulations are protected by U.S. Patent 8,524,773?

The patent's formulation protection is limited but commercially relevant. The claims expressly identify:

Micro-pellets.
Micro-tablets.
Granulates.
Capsules.
Tablets.

Claims 3 and 4 do not appear to require a specific dose, particle size, coating, dissolution profile, or release period. This makes the claim potentially broad across solid oral dosage forms, but the claim must still be read with the requirement that the preparation consists essentially of dimethyl fumarate and is administered orally for multiple sclerosis.

The patent does not, based on the quoted claims, expressly cover:

Intravenous administration.
Transdermal delivery.
Inhaled administration.
A formulation containing only methyl hydrogen fumarate rather than dimethyl fumarate.
A product used for a non-multiple-sclerosis disease.
A manufacturing process for dimethyl fumarate.
A specific enteric coating or controlled-release technology.

Separate formulation patents may provide stronger protection for release profiles, gastrointestinal tolerability, particle engineering, or specific excipient systems.

Is biosimilar risk relevant to Tecfidera?

No. Dimethyl fumarate is a chemically synthesized small molecule, not a biologic. Competitors enter through the ANDA pathway for generic drugs rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive risks are:

Abbreviated new drug applications.
Paragraph IV certifications.
Section viii labeling strategies.
Generic substitution.
Authorized generic supply.
Post-expiry price erosion.
Alternative multiple-sclerosis therapies.

Biosimilar patent procedures, reference-product exclusivity for biologics, and the patent dance do not govern ordinary dimethyl fumarate entry.

How does dimethyl fumarate compare with competing multiple-sclerosis drugs?

Dimethyl fumarate competes with oral, injectable, and infusion therapies. Key branded alternatives include teriflunomide, fingolimod, ozanimod, cladribine, natalizumab, ocrelizumab, ofatumumab, and other disease-modifying therapies.

Product class	Example	Entry pathway	Patent-landscape profile
Oral small molecule	Dimethyl fumarate	ANDA generic entry	Method and formulation patents
Oral small molecule	Teriflunomide	ANDA generic entry	Compound, method, and formulation patents
Oral small molecule	Fingolimod	ANDA generic entry	Compound, formulation, and method patents
Monoclonal antibody	Ocrelizumab	Biosimilar pathway	Biologic patents and regulatory exclusivity
Monoclonal antibody	Natalizumab	Biosimilar pathway	Biologic and manufacturing patents
Injectable biologic	Interferon products	Biosimilar or specialty pathways	Manufacturing and formulation rights

Dimethyl fumarate has a greater near-term generic-substitution risk than biologic multiple-sclerosis products because an ANDA applicant can rely on the reference product's safety and efficacy findings. The patent estate, rather than clinical comparability, is the principal legal barrier.

Does U.S. Patent 8,524,773 block generic launch?

It can block or delay a generic launch if the patent is listed, enforceable, not expired, and infringed by the proposed product and labeling. It does not automatically block FDA approval in every scenario. The outcome depends on the certification, litigation, claim construction, settlement terms, and final patent status.

The most exposed product is an oral dimethyl fumarate tablet or capsule expressly labeled to treat multiple sclerosis. A product with a carved-out label, a different dosage form, or a noninfringing use may present a lower risk, although induced-infringement and product-label evidence remain important.

Key Takeaways

U.S. Patent 8,524,773 is a method-of-treatment patent, not a basic compound patent.
Claim 1 focuses on contacting PBMCs or monocytes with methyl hydrogen fumarate.
Claim 2 reaches oral dimethyl fumarate that converts in vivo into methyl hydrogen fumarate.
Claims 3 and 4 cover solid oral dosage forms, with claim 4 specifically covering tablets and capsules.
Claim 5 is limited to micro-tablets.
The patent's commercial relevance is strongest against generic dimethyl fumarate products labeled for multiple sclerosis.
FDA exclusivity and patent exclusivity are separate. Tecfidera's five-year NCE exclusivity expired in 2018, while patent rights continued afterward.
The public patent record identifies a 2028 expiration period for the '773 patent, subject to the official USPTO term calculation.
The Federal Circuit's invalidation of a separate Tecfidera patent, U.S. Patent No. 8,399,514, does not automatically resolve the validity or enforceability of U.S. Patent 8,524,773.
Biosimilar risk is not applicable because dimethyl fumarate is a small molecule.
Generic launch risk depends on the ANDA certification, labeling, dosage form, Orange Book status, litigation outcome, and any settlement or license.

FAQs

Can a generic dimethyl fumarate capsule infringe U.S. Patent 8,524,773?

Yes. A capsule labeled for treating multiple sclerosis could satisfy claim 4 if it contains a preparation consisting essentially of dimethyl fumarate and the other claim limitations are met.

Does the patent cover monomethyl fumarate as a standalone drug?

The quoted claims do not expressly claim administration of standalone methyl hydrogen fumarate as the finished oral product. Claim 2 specifically requires an oral preparation consisting essentially of dimethyl fumarate.

Can a generic avoid the patent by changing inactive ingredients?

Not necessarily. The claims do not require the same excipients as the reference product. Changing inactive ingredients may avoid other formulation patents but may not avoid claim 2 or claim 4.

Does a micro-tablet product face greater risk than a conventional tablet?

It may face a more direct risk under claim 5, which expressly recites micro-tablets. A conventional tablet or capsule is more directly relevant to claim 4.

Is a patent invalidated in Tecfidera litigation automatically removed from the entire patent estate?

No. Each patent must be evaluated independently. A judgment involving U.S. Patent No. 8,399,514 does not automatically determine the validity, enforceability, or infringement of U.S. Patent No. 8,524,773.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,524,773. https://patents.google.com/patent/US8524773
U.S. Food and Drug Administration. (2013, March 27). FDA approves new multiple sclerosis treatment. https://www.fda.gov/news-events/press-announcements/fda-approves-new-multiple-sclerosis-treatment
Biogen International GmbH v. Mylan Pharmaceuticals Inc., 18 F.4th 1333 (Fed. Cir. 2021).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	198 53 487	Nov 19, 1998

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1131065	⤷ Start Trial	C300675	Netherlands	⤷ Start Trial
European Patent Office	1131065	⤷ Start Trial	CA 2014 00036	Denmark	⤷ Start Trial
European Patent Office	1131065	⤷ Start Trial	PA2014023	Lithuania	⤷ Start Trial
European Patent Office	1131065	⤷ Start Trial	92488	Luxembourg	⤷ Start Trial
European Patent Office	1131065	⤷ Start Trial	39/2014	Austria	⤷ Start Trial
European Patent Office	1131065	⤷ Start Trial	1490039-3	Sweden	⤷ Start Trial
European Patent Office	1131065	⤷ Start Trial	518	Finland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,524,773

Summary for Patent: 8,524,773